Management of irritable bowel syndrome: Start of a new era?

European Journal of Gastroenterology and Hepatology

Volumn 15, Issue 6, 2003, Pages 679-696

  Silk, D B A ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b EALING HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; ASIMADOLINE; CELLULOSE; CILANSETRON; CODEINE PHOSPHATE; DIPHENOXYLATE; FEDOTOZINE; HYDROGEN; KAPPA OPIATE RECEPTOR AGONIST; LOPERAMIDE; METHANE; PAROXETINE; POLYSACCHARIDE; PROBIOTIC AGENT; PRUCALOPRIDE; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT;

ANTIBIOTIC THERAPY; ANXIETY; BARIUM ENEMA; CLINICAL FEATURE; CLINICAL TRIAL; COLON ABSORPTION; COLON MOTILITY; COLONOSCOPY; CONSTIPATION; COST OF ILLNESS; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DIET; DIET THERAPY; DIGESTION; DRUG EFFECT; ECONOMIC ASPECT; FERMENTATION; FLATULENCE; FOOD COMPOSITION; FOOD INTAKE; FOOD PREFERENCE; GASTROINTESTINAL INFECTION; GASTROINTESTINAL TRACT; HEALTH CARE COST; HUMAN; HYPERALGESIA; HYPOCHONDRIASIS; HYSTERECTOMY; INTESTINE FUNCTION; INTESTINE MOTILITY; IRRITABLE COLON; ISCHEMIC COLITIS; LAPAROSCOPY; LIFE EVENT; MAST CELL; MEDICAL RESEARCH; MEDICAL SPECIALIST; NONHUMAN; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; RECTUM; REVIEW; RISK FACTOR; SENSITIZATION; SEX DIFFERENCE; SIGMOID; SMALL INTESTINE; SOCIAL ASPECT; SOCIAL PSYCHOLOGY; STRESS; VISCERAL PAIN;

COLONIC DISEASES, FUNCTIONAL; DIET; GASES; GASTROENTERITIS; GASTROINTESTINAL AGENTS; HUMANS; INFECTION; INTESTINES;

EID: 0038460050     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200306000-00016     Document Type: Review

References (246)

1. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, et al. US householder survey of functional gastrointestinal disorders. Dig Dis Sci 1993; 38:1569-1580.
2. Silk DBA. Impact of irritable bowel syndrome on personal relationships and working practices. Eur J Gastroenterol Hepatol 2001; 13:1327-1332.
3. Longstreth GF, Olde-Tsadik G. Irritable bowel-type symptoms in HMO examinees. Dig Dis Sci 1993; 38:1581-1589.
4. Jones R, Lydiard S. Irritable bowel syndrome in the general population. BMJ 1992; 304:87-90.
5. Talley NJ, Weaver A, Zingmeister AR, Melton LJ. Incidence and disappearance of functional gastrointestinal disorders. Gut 1991; 32:A1249.
6. Thompson WG, Heaton KW. Functional bowel disorders in apparently healthy people. Gastroenterology 1980; 79:283-288.
7. Bommelaer G, Rouch M, Dapoigny M, Pais D, Loisy P, Gualinjo M, Tournut R. Epidemiologie des troubles functionnels intestinaux dans une population appaermment saine. Gastroenterol Clin Biol 1986; 10:7-12.
8. Drossman DA, Sandler RS, McKee DC, Lovits AJ. Bowel patterns among subjects not seeking health care. Gastroenterology 1982; 83:529-534.
9. Sandler RS, Drossman DA, Nathan HP, McKee DC. Symptom complaints and health care seeking behaviour in subjects with bowel dysfunction. Gastroenterology 1984; 87:314-318.
10. Sandler RS, Broom, CM, McKee DC. Urgency and faecal soiling in people with bowel dysfunction. Dig Dis Sci 1986; 292:1221-1225.
11. Johnsen R, Jacobsen BK, Forde OH. Associations between symptoms of irritable colon and psychological and social conditions and lifestyle. BMJ 1986; 292:1633-1635.
12. Macdonald AJ, Bouchier PAD. Non organic gastrointestinal illness: a medical and psychiatric study. Br J Psychol 1980; 136:276-283.
13. Craig TK, Brown GW. Goal frustrating aspects of life event stress in the aetiology of gastrointestinal disorder. J Psychosom Res 1984; 28:411-421.
14. Ford MJ, Miller P, Eastwood J, Eastwood MA. Life events, psychiatric illness and the irritable bowel syndrome. Gut 1987; 28:160-165.
15. Heaton KW, O'Donnel LJD, Braddon FEM, Mountford RA, Hughes AO, Cripps PJ. Symptoms of irritable bowel syndrome in a British urban community: consulters and non consulters. Gastroenterology 1992; 102:1962.
16. Gomborone JE, Dewsnap PA, Libby GW, Farthing MJ. Community study reveals that dysfunctional illness attitudes in irritable bowel syndrome are not wholly a reflection of patient status. Gastroenterology 1993; 104 (part 2):A513.
17. Gomborone JE, Dewsnap PA, Libby GW, Farthing MJ. Abnormal illness attitudes in irritable bowel syndrome. J Psychosom Res 1995; 39:227-230.
18. Weber FH, McCullum RW. Clinical approaches to irritable bowel syndrome. Lancet 1992; 340:1447-1451.
19. Harvey RF, Salih SY, Read AE. Organic and functional disorders in 2000 gastroenterology outpatients. Lancet 1983; 95:632-634.
20. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome: the view from general practice. Eur J Gastroenterol Hepatol 1997; 9:689-692.
21. Guthrie EA, Creed FH, Whorwell PJ, Tomenson B. Outpatients with IBS: a comparison of first time and chronic attenders. Gut 1992; 33:361-363.
22. Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. Gut 1986; 27:37-40.
23. Whorwell PJ. Non colonic aspects of IBS. IBS Monitor 1995; 1:7-8.
24. Maxton DG, Morris J, Whorwell PJ. Ranking of symptoms by patients with irritable bowel syndrome. BMJ 1989; 299:1138-1139.
25. Prior A, Wilson K, Whorwell PJ, Paragher EB. Irritable bowel syndrome in the gynaecological clinic: a survey of 798 new referrals. Dig Dis Sci 1989; 34:1820-1824.
26. Francis CY, Duffy JN, Whorwell PJ, Morris J. High prevalence of irritable bowel syndrome in patients attending urological outpatient departments. Dig Dis Sci 1997; 42:404-407.
27. Prior A, Whorwell PJ. Gynaecological consultations in patients with irritable bowel syndrome. Gut 1989; 30:996-998.
28. Jones J, Boorman J, Cann P, Forbes A, Gomborone J, Heaton K, et al. British Society of Gastroenterology guidelines for the management of irritable bowel syndrome. Gut 2000; 47 (suppl 11):1-9.
29. Corney RH, Stanton R. Physical symptoms severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome. J Psychosom Res 1990; 34:483-491.
30. Wells NEJ, Halin BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther 1997; II:1019-1030.
31. Silk DB. Patients' views on IBS. Int J Gastroenterol 1998; 3:20-22.
32. Horwitz BJ, Fisher RS. The irritable bowel syndrome. N Engl J Med 2001; 334:1846-1850.
33. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987; 92:1885-1893.
34. Small PK, Loudon MA, Han CM, Noor N, Campbell FC. Large scale ambulatory study of post prandial jejunal motility in irritable bowel syndrome. Scand J Gastroenterol 1997; 32:39-47.
35. Schmidt T, Hackelsberger N, Widmer R, Meisel C, Pfeiffer A, Kaess H. Ambulatory 24 hour jejunal motility in diarrhoea-predominant irritable bowel syndrome. Scand J Gastroenterol 1996; 31:581-589.
36. Rogers J, Henry MM, Misiewicz JJ. Increased segmental activity and intraluminal pressures in the sigmoid colon of patients with the irritable bowel syndrome. Gut 1989; 30:634-641.
37. Maxton DG, Martin DF, Whorwell PJ, Godfrey M. Abdominal distension in female patients with irritable bowel syndrome: exploration of possible mechanisms. Gut 1991; 32:662-664.
38. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973; 14:125-132.
39. Whitehead WE, Holtkotter B, Enck P, Hoelzl R, Holmes KD, Anthony J, et al. Tolerance for rectosigmoid distension in irritable bowel syndrome. Gastroenterology 1990; 98:1187-1192.
40. Kellow JE, Phillips SF, Miller LJ, Zinsmeister AR. Dysmotility of the small intestine in irritable bowel syndrome. Gut 1988; 29:1236-1243.
41. Bonaz BL, Papillon E, Baciu M, Segebarth C, Bost R, LeBas J, Fournet J. Central processing of rectal pain in IBS patients: an MRI study. Gastroenterology 2000; 118 (suppl):A615.
42. Mertz H, Morgan V, Tanner G, Pickens D, Price R, Shyr Y, Kessler R. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distension. Gastroenterology 2000; 118:842-848.
43. Ringel Y, Drossman DA, Turkington TG, Hawk TC, Bradshaw BH, Coleman RE, Whitehead WE. Dysfunction of the motivational-affective pain system in patients with IBS: PET brain imaging in response to rectal balloon distension. Gastroenterology 2000; 118 (suppl):A444.
44. Silverman DHS, Munakata JA, Ennes H, Mandelkern MA, Hoh CK, Mayer EA. Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 1997; 112:64-72.
45. Walker EA, Roy-Byrne PP, Katon WJ, Li L, Amos D, Jiranek G. Psychiatric illness and irritable bowel syndrome: a comparison with inflammatory bowel disease. Am J Psychiatry 1990; 147:1656-1661.
46. Bennett EJ, Tennant CC, Piesse C, Badcock CA, Kellow JE. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut 1998; 43:256-261.
47. Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Gastrointestinal tract symptoms and self-reported abuse: a population-based study. Gastroenterology 1994; 107:1040-1049.
48. Garcia-Rodrigues LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999; 318:565-566.
49. Gwee KA, Graham JC, McKendric MW, Collins S, Marshall JS, Walters SJ, Read NW. Psychometric scores and persistence of irritable bowel syndrome after infectious diarrhoea. Lancet 1996; 347:150-153.
50. Neal KR, Hebden J, Spiller RC. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1992; 314:779-782.
51. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, et al. The role of psychological and biological factors in post infective gut dysfunction. Gut 1999; 44:400-406.
52. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47:804-811.
53. Alun-Jones V, Wilson AJ, Hunter JO, Robinson RE. The aetiological role of antibiotic prophylaxis with hysterectomy in irritable bowel syndrome. J Obstet Gynaecol 1984; 5:522-523.
54. Mendal MA I, Kumar D. Antibiotic use, childhood affluence and irritable bowel syndrome (IBS). Eur J Gastroenterol Hepatol 1998; 10:59-62.
55. Maxwell PR, Rink E, Kumar D, Mendall MA. Antibiotics increase functional abdominal symptoms. Am J Gastroenterol 2002; 97:104-108.
56. Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G. The faecal microbial population in the irritable bowel syndrome. Microbiologica 1982; 5:185-194.
57. Bradley HK, Wyatt GM, Bayliss CE, Hunter JO. Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol 1987; 23:29-32.
58. Madden JAS, Plummer S, Sen S, Dear K, Tarry S, Hunter JO. Comparison of the caecal and faecal microflora of healthy subjects and patients with irritable bowel syndrome (IBS). Gut 2001; 48 (suppl 1):A58.
59. King TS, Elia M, Hunter J. Evidence for abnormal fermentation in the irritable bowel syndrome. Lancet 1998; 352:1187-1189.
60. Di-Stefano M, Strocchi A, Malservisc S, Veneto G, Ferrieri A, Corazza GR. Non-absorbable antibiotics for managing intestinal gas production and gas related symptoms. Aliment Pharmacol Ther 2000; 14:1001-1008.
61. Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8:159-166.
62. Macfarlane GT, Gibson GR, Cummings JH. Comparison of fermentation reactions in different regions of the human colon. J Appl Bacteriol 1983; 72:57-64.
63. Lasser RB, Bond JH, Levitt MD. The role of intestinal gas in functional abdominal pain. N Engl J Med 1975; 293:524-526.
64. Serra J, Azpiroz F, Malagelada J-R. Impaired transit and tolerance of gas in the irritable bowel syndrome. Gut 2001; 48:14-19.
65. Calderella MP, Serra J, Azpiroz F, Malagelada JR. Prokinetic effects in patients with intestinal gas retention. Gastroenterology 2002; 122:1748-1755.
66. Nanda R, James R, Smith H, Dudley CR, Jewell DP. Food intolerance and the irritable bowel syndrome. Gut 1989; 30:1099-1104.
67. Simren M, Mansson A, Langkilde AM, Svedlund J, Abrahamsson H, Bengtsson U, Bjoensson ES. Digestion 2001; 62:108-115.
68. Jones VA, McLaughlan P, Shorthouse M, Workman E, Hunter JO. Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome. Lancet 1982; ii:1115-1117.
69. Bentley SJ, Pearson DJ, Rix KJ. Food hypersensitivity in irritable bowel syndrome. Lancet 1983; ii:295-297.
70. Farah DA, Calder I, Benson L, MacKenzie JF. Specific food intolerance: its place as a cause of gastrointestinal symptoms. Gut 1985; 26:164-168.
71. McKee AM, Prior A, Whorwell PJ. Exclusion diets in irritable bowel syndrome: are they worthwhile? J Clin Gastroenterol 1987; 9:526-528.
72. Zwetchkenbaum JF, Burakoff R. Food allergy and the irritable bowel syndrome. Am J Gastroenterol 1988; 83:901-904.
73. Silk DBA. Diet and IBS. IBS Bulletin 1997; 14:i-viii.
74. Smart HL, Mayberry UF, Atkinson M. Alternative medicine consultations and remedies in patients with the irritable bowel syndrome. Gut 1986; 27:826-828.
75. 2 excretion after ingestion of complex carbohydrates. Gastroenterology 1987; 92:383-389.
76. Hyams JS. Sorbitol intolerance: an unappreciated cause of functional gastrointestinal complaints. Gastroenterology 1983; 84:30-33.
77. Rumessen JJ, Gudmand-Hoyer E. Functional bowel disease: malabsorption and abdominal distress after ingestion of fructose, sorbitol and fructose-sorbitol mixtures. Gastroenterology 1988; 95:694-700.
78. Barau E, Dupont C. Modifications of intestinal permeability during food provocation procedures in pediatric irritable bowel syndrome. J Pediatr Gastroenterol Nutr 1990; 11:72-77.
79. Kolmannskog S, Haneberg B. Immunoglobulin E in faeces from children with allergy. Evidence of local production of IgE in the gut. Int Arch Allergy Appl Immunol 1985; 76:133-137.
80. Awazuhara H, Kawai H, Maruchi N. Major allergens in soybean and clinical significance of IgE4 antibodies investigated by IgE- and IgE4-immunoblotting with sera from soybean-sensitive patients. Clin Exp Allergy 1997; 27:325-332.
81. Bassotti G, Bertollo A, Spinozzi F. Heretical thoughts about food hypersensitivity: small bowel manometry as an objective way to document gut reactions. Eur J Clin Nutr 1997; 51:567-572.
82. Santos J, Saperas E, Nogveiras C, Mourelle M, Antolin M, Cadakia A, Malagelada J-R. Release of mast cell mediators into the jejunum by cold pain stress in humans. Gastroenterology 1998; 114:640-648.
83. Castagliuolo I, Lamont JT, Qiu B, Fleming SM, Bhaskar KR, Nikulasson ST, et al. Acute stress causes mucin release from rat colon: role of corticotropin releasing factor and mast cells. Am J Physiol 1996; 271:G884-892.
84. Theoharides TC, Letourneau R, Patra P, Hesse L, Pang X, Boucher W, et al. Stress-induced rat intestinal mast cell intragranular activation and inhibitory effect of sulfated proteoglycans. Dig Dis Sci 1999; 44 (suppl 8):87S-93S.
85. Lenz HJ, Readler A, Greten H, Vale WW, Rivier JE. Stress-induced gastrointestinal secretory and motor responses in rats are mediated by endogenous corticotrophin-releasing factor. Gastroenterology 1998; 95:1510-1517.
86. Gue M, Junien JL, Bueno I. Conditioned emotional response in rats enhances colonic motility through the central release of corticotrophin-releasing factor. Gastroenterology 1991; 100:964-970.
87. Monnikers H, Schmidt BG, Tache Y. Psychological stress induced accelerated colonic transit in rats involves hypothalamic corticotrophin-releasing factor. Gastroenterology 1993; 104:716-723.
88. Williams CL, Peterson JM, Villar RG, Burks TF. Corticotrophin-releasing factor directly mediates colonic response to stress. Am J Physiol 1987; 253:G582-586.
89. Fukudo S, Nomura T, Hongo M. Impact of corticotrophin releasing hormone on gastrointestinal motility and adrenocorticotrophic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998; 42:845-849.
90. Eskay RL, Grino M, Chen HT. Interleukins, signal transduction and the immune system-mediated stress response. Adv Exp Med Biol 1990; 274:331-343.
91. Van Gool J, van Vugt H, Helle M, Aarden LA. The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat. Clin Immunol Immunopathol 1990; 57:200-210.
92. Shanahan F, Anton P, Neuroendocrine modulation of the immune system. Possible implications for inflammatory bowel disease. Dig Dis Sci 1988; 33:41S-49S.
93. Barclay GR, Turnberg LA. Effect of cold induced pain on salt and water transport in the human jejunum. Gastroenterology 1988; 94:994-998.
94. Longstreth GF, Preskill DB, Youkeles L. Irritable bowel syndrome in women having diagnostic laparoscopy or hysterectomy. Dig Dis Sci 1990; 35:1285-1290.
95. Whitehead WE, Winget C, Fedoraricius AS, Wooley S, Blackwell B. Learned illness behaviour in patients with irritable bowel syndrome and peptic ulcer. Dig Dis Sci 1982; 27:202-208.
96. Prior A, Stanley KM, Smith ARB, Read NW. Relation between hysterectomy and the irritable bowel: a prospective study. Gut 1992; 33:814-817.
97. Heaton KW, Parker D, Cripps H. Bowel function and irritable bowel syndrome after hysterectomy and cholecystectomy - a population based study. Gut 1993; 34:1108-1111.
98. Penagini R, Spiller RC, Misiewicz JJ, Frost PC, Silk DBA. Effect of cholecystectomy on mouth to caecum transit of a liquid meal. Dig Dis Sci 1988; 33:19-22.
99. Ros E, Zambon D. Postcholecystectomy symptoms. A prospective study of gall stone patients before and two years after surgery. Gut 1987; 28:1500-1504.
100. Edwards CA, Brown S, Baxter AJ, Bannister JS, Read NW. Effect of bile acid on anorectal function in man. Gut 1989; 30:383-386.
101. Crowen MD, Cheskin LJ, Musial F. Prevalence of gastrointestinal symptoms in obese and normal weight binge eaters. Am J Gastroenterol 1994; 89:3-7.
102. Hutson WR, Wald A. Gastric emptying in patients with bulimia nervosa and anorexia nervosa. Am J Gastroenterol 1990; 85:41-46.
103. Chami TN, Andersen AE, Crowell MD, Schuster MM, Whitehead WE. Gastrointestinal symptoms in bulimia nervosa: effects of treatment. Am J Gastroenterol 1995; 90:88-92.
104. Abraham SF, Beumont PJV. How patients describe bulimia or binge eating. Psychiatry Med 1982; 12:625-635.
105. Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut 1999; 45 (suppl 11):111-115.
106. Drossman DA, Richter JE, Talley NJ, Thompson WG, Coraziari E, Whitehead WE (editors). The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment, 1st edn. Mclean VA: Degnon Associates; 1994.
107. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (suppl 11):1143-1147.
108. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised placebo controlled trial. Lancet 2000; 355:1035-1040.
109. Heaton KW. Irritable bowel syndrome. In: Bouchier IAD, Allen RN, Hodgson JHF, Keighley MRB (editors). Textbook of Gastroenterology. London: Bailliere Tindall; 1984. pp. 867-875.
110. Cole SJ, Duncan HD, Claydon AH, Austin D, Bowling TJ, Silk DBA. Distal colonic motor activity in four subgroups of patients with irritable bowel syndrome. Dig Dis Sci 2002; 47:345-355.
111. Camilleri M, Choi M-G. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11:3-15.
112. Farthing MJ. Irritable bowel, irritable body or irritable brain? BMJ 1995; 310:171-175.
113. Niec AM, Frankum B, Talley NJ. Are adverse food reactions linked to irritable bowel syndrome? Am J Gastroenterol 1998; 93:2184-2190.
114. Parker TJ, Naylor SJ, Riordan AM, Hunter JO. Management of patients with food intolerance in irritable bowel syndrome: the development and use of an exclusion diet. J Hum Nutr Dietetics 1995; 8:159-166.
115. Ferguson A, Macdonald DM, Brydon WG. Prevalence of lactose deficiency in British adults. Gut 1984; 25:163-167.
116. Parker TJ, Woolner JT, Prevost AT, Tuffnell Q, Shorthouse M, Hunter JO. Irritable bowel syndrome: is the search for lactose intolerance justified? Eur J Gastroenterol Hepatol 2001; 13:219-225.
117. Böhmer CJM, Tuynmen HARE. The effect of a lactose-restricted diet in patients with a positive lactose tolerance test, earlier diagnosed as irritable bowel syndrome: a 5-year follow up. Eur J Gastroenterol Hepatol 2001; 13:941-944.
118. Suarez FL, Savaiano DA, Levitt MD. A comparison of symptoms after the consumption of milk or lactose-hydrolysed milk by people with self-reported severe lactose intolerance. N Engl J Med 1995; 333:1-4.
119. Arffmann S, Andersen JR, Hegnhoj J, Schaffalitzky de Muckadell OB, Mogensen NB, Krag E. The effect of coarse wheat bran in the irritable bowel syndrome. Scand J Gastroenterol 1985; 20:295-298.
120. Lucey MR, Crark ML, Lowndes J, Dawson AM. Is bran efficacious in irritable bowel syndrome? Gut 1987; 28:221-225.
121. Cook IJ, Irvine EJ, Campbell D, Shannon S, Reddy SN, Collins SM. Effect of dietary fibre on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. Gastroenterology 1990; 98:66-72.
122. Richie JA, Truelove SC. Treatment of irritable bowel syndrome with lorazepam, hyoscine butyl bromide and ispaghula husk. BMJ 1979; i:376-378.
123. Prior A, Whorwell PJ, Double blind study of ispaghula in irritable bowel syndrome. Gut 1987; 28:1510-1513.
124. Toskes PP, Connery KL, Ritchey TW. Carcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7:87-92.
125. Snook J, Shepherd HA. Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8:511-514.
126. Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet 1994; 344:39-40.
127. Southgate DAT, Hudson GJ, Englyst H. The analysis of dietary fibre - the choices for the analyst. J Sci Food Agric 1978; 29:979-988.
128. Englyst H. Determination of carbohydrate and its composition in plant material. In: James WPT, Theander O (editors). The Analysis of Dietary Fibre in Food. New York: Dekker; 1981. pp. 71-93.
129. Salyers AA, Leedle JAZ. Carbohydrate metabolism in the human colon. In: Hentges DJ (editor). Human Intestinal Microflora in Health and Disease. New York: Academic Press; 1983. pp. 129-146.
130. Salyers AA, Palmer JK, Wilkins TD. Degradation of polysaccharides by intestinal bacterial enzymes. Am J Clin Nutr 1978; 31 (suppl 100):5128-5130.
131. Stephen AM, Cummings JH. Mechanism of action of dietary fibre in the human colon. Nature 1980; 284:283-284.
132. Silk DBA. Fibre and enteral nutrition. Gut 1989; 30:246-264.
133. Van Soest PJ, Robertson JB, Roe DA, Rivers J, Lewis BA, Hackler IR. The role of dietary fibre in human nutrition. In: Proceedings 1978, Cornell Nutrition Conference for Feed Manufacturers, 1978. pp. 5-12.
134. Cummings JH. Consequences of the metabolism of fibre in the human large intestine. In: Vahouny GV, Kritchersky D (editors). Dietary Fibre in Health and Disease. New York: Plenum Press; 1982. pp. 9-22.
135. Ehle FR, Robertson JB, Van Soest PJ. Influence of dietary fibres on fermentation in the human large intestine. J Nutr 1982; 112:158-166.
136. Heller SN, Hackler LR, Rivers JM, Van Soest PJ, Roe DA, Lewis BA, Robertson J. Dietary fibre: the effect of particle size of wheat bran on colonic function in young men. Am J Clin Nutr 1980; 33:1734-1744.
137. Eastwood MA, Bryden WC, Tadasse K. Effect of fibre on colon function. In: Spiller GA, Kay RM (editors). Medical Aspects of Dietary Fibre. New York: Plenum Press; 1980. pp. 1-26.
138. Lauria SE. The bacterial protoplasm: composition and organisation. In: Gunsalus IC, Stainer RY (editors). Bacteria, Vol. 1. New York: Academic Press; 1960. pp. 1-34.
139. Moriarty KJ, Silk DBA. Laxative abuse. Dig Dis 1988; 6:15-29.
140. Attar A, Lemann M, Ferguson A, Halphen M, Boutron C, Flourie B, et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut 1999; 44:226-230.
141. Patil DH, Westaby D, Mahida YR, Palmer KR, Rees R, Clark ML, et al. Comparative modes of action of lactilol and lactulose in the treatment of hepatic encephalopathy. Gut 1987; 28:255-259.
142. Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhoea-predominant irritable bowel syndrome. Dig Dis Sci 1985; 40:86-95.
143. Klein KB. Controlled treatment trials in the irritable bower syndrome: a critique. Gastroenterology 1988; 95:232-241.
144. Poynard T, Regimbeau C, Benhamouy. Meta-analysis of smooth muscle relaxants in the treatment of irritable bower syndrome. Aliment Pharmacol Ther 2001; 15:355-361.
145. Mitchell SA, Mee AS, Palmer KR, Chapman RW. Alverine citrate (spasmonal) fails to relieve the symptoms of irritable bowel syndrome; results of a double blind, randomised placebo controlled trial. Gut 2001; 48 (suppl 1):A46.
146. Blanchard EB, Greene B, Scharff L, Schwarz-McMorris SP. Relaxation training as a treatment for irritable bowel syndrome. Biofeedback Self Regul 1993; 18:125-132.
147. Virol MW, Hipolito J. Anthropo-analytical relaxation in irritable bowel syndrome: results 40 months later. Schweiz Med Wochenschr 1987; 117:1117-1119.
148. Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy in the treatment of severe refractory irritable bowel syndrome. Lancet 1984; ii:1232-1233.
149. Whorwell PJ. Use of hypnotherapy in gastrointestinal disease. Br J Hosp Med 1991; 45:27-29.
150. Whorwell PJ, Houghton LA, Taylor EE, Maxton DG. Physiological effects of emotion: assessment via hypnosis. Lancet 1992; 346:69-70.
151. Houghton LA, Heyman DJ, Whorwell PJ. Symptomatology, quality of life and economic features of irritable bowel syndrome - the effect of hypnotherapy. Aliment Pharmacol Ther 1996; 10:91-95.
152. Vidakovic-Vukic M. Hypnotherapy in the treatment of irritable bowel syndrome. Methods and results in Amsterdam. Scand J Gastroenterol 1999; 34 (suppl 230):49-51.
153. Greene B, Blanchard EB. Cognitive therapy for irritable bowel syndrome. J Consult Clin Psychol 1994; 62:576-582.
154. Payne A, Blanchard EB. Controlled comparison of cognitive therapy and self-help support groups in the treatment of irritable bowel syndrome. J Consult Clin Psychol 1995; 63:779-786.
155. Guthrie E, Creed F, Dawson D, Tomenson B. A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology 1991; 100:450-457.
156. Guthrie E, Brief psychotherapy with patients with refractory irritable bowel syndrome. Br J Psychother 1991; 8:175-188.
157. Svedlund J, Sjodin I, Ottosson J, Dotevall G. Controlled study of psychotherapy in irritable bowel syndrome. Lancet 1988; ii:589-592.
158. Liss JL, Alpers D, Woodruff RA Jr. The irritable colon syndrome and psychiatric illness. Dis Nerv Syst 1973; 34:151-157.
159. Clouse RE, Alpers DH. The relationship of psychiatric disorder to gastrointestinal illness. Annu Rev Med 1986; 37:283-295.
160. Walker EA, Roy-Byrne PP, Katon WJ. Irritable bowel syndrome and psychiatric illness. Am J Psychiatry 1990; 147:565-572.
161. Gerard DA, Libby GW, Farthing MJ. 5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine uptake. Gut 1994; 34:496-500.
162. Myren J, Lovland B, Larssen SE, Larsen S. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol 1984; 19:835-843.
163. Myren J, Groth H, Larssen SE. The effect of trimipramine in patients with the irritable bowel syndrome. A double blind study. Scand J Gastroenterol 1982; 17:871-875.
164. Greenbaum DS. Preliminary report on antidepressant treatment of irritable bowel syndrome: comments on comparison with anxiolytic therapy. Psychopharmacol Bull 1984; 20:622-628.
165. Steinhart MJ, Wong PY, Zarr ML. Therapeutic usefulness of amitriptyline in spastic colon syndrome. Gastroenterology 1980; 78:1270-1272.
166. Greenbaum DS, Mayle JE, Vanegeren LE, Jeroe JA, Mayor JW, Greenbaum RB, et al. Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci 1987; 32:257-266.
167. Riviere P, Pascaud X, Chevalier E, Le Gallou B, Junien JL. Fedotozine reverses ileus induced by surgery or peritonitis. Action at peripheral kappa opioid receptors. Gastroenterology 1993; 104:724-731.
168. Diop L, Riviere P, Pascaud X, Junien JL. Peripheral kappa-opioid receptors mediate the antinociceptive effect of fedotozine on the duodenal pain reflex in rat. Eur J Pharmacol 1994; 271:65-71.
169. Langlois A, Diop L, Riviere PJ, Pascaud X, Junien JL. Effect of fedotozine on the cardiovascular pain reflex induced by distension of the irritated colon in the anaesthetized rat. Eur J Pharmacol 1994; 271:245-251.
170. Riviere P, Pascaud X, Chavalier E, Junien JL. Fedotozine reversal of peritoneal-irritation-induced ileus in rats: possible peripheral action on sensory afferents. J Pharmacol Exp Ther 1994; 270:846-850.
171. Delvaux M, Louvel D, Lagier E, Scherrer B, Abitbol J-L, Frexinos J. The K-agonist fedotozine relieves hypersensitivity to colonic distension in patients with irritable bowel syndrome. Gastroenterology 1999; 116:38-45.
172. Dapiogny M, Abitbol J-L, Fraitag B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicentre dose-response study. Dig Dis Sci 1995; 40:2244-2248.
173. Delgado-Aros S, Chial H, Ferber I, Szarka L, Pardi D, McKinzies Burton D, et al. The K-opioid agonist asimadoline decreases satiety and fasting colonic tone in humans. Gastroenterology 2002; 122 (suppl):A101.
174. Gershon MD. Enteric nervous system: neural connections, neurotransmitters, and the function of 5-hydroxytryptamine. In: Kamm MA, Lennard-Jones JE (editors). Gastrointestinal Transit - Pathophysiology and Pharmacology. Petersfield, UK: Wrightson Biomedical Publishing; 1991. pp. 21-32.
175. 3 receptor antagonist (ICS 205-930) on colonic motor activity in healthy men. Br J Clin Pharmacol 1989; 28:315-322.
176. Gore S, Gilmore IT, Haigh CG, Brownless SM, Stockdale H, Morris AIC. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther 1990; 4:139-144.
177. Talley NJ, Phillips SF, Haddad A, Miller LJ, Twomey C, Zinsmeister AR, et al. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990; 35:477-480.
178. 3 receptor antagonist, in patient with irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7:175-180.
179. Zieghelboim J, Talley NJ, Phillips SF, Harmsen WS, Zinsmeister AR. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Dig Dis Sci 1995; 40:819-827.
180. Goldberg PA, Kamm MA, Setti-Carraro P, van der Sijp JRM, Roth C. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5HT3 antagonism (ondansetron). Digestion 1996; 57:748-783.
181. Bardhan KD, Bodemar G, Geldof H, Schutz E, Heath A, Mills JG, Jacques LA. A double-blind placebo-controlled study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14:23-34.
182. Camilleri M, Mayer EA, Drossman DA, Heath A, Dukes GE, McSorley D, et al. Improvement in pain and bowel function in female irritable bowel syndrome patients with alosetron, a 5-HT3-receptor antagonist. Aliment Pharmacol Ther 1999; 14:1149-1151.
183. McColl KEL. Alosetron in irritable bowel syndrome. Lancet 2000; 365:164.
184. Kress S. Summary of serious adverse G.I. events associated with alosetron. CDER. HFT-180 June 2000.
185. Beubier E, Schirgi-Degen A. Serotonin antagonists inhibit sennoside-induced fluid secretion and diarrhoea. Pharmacology 1993; 47 (suppl 1):64-69.
186. Hansen MB, Skadhauge E. Ketanserin and granisetron reduce cholera toxin-induced hypersecretion in pig jejunum. Scand J Gastroenterol 1994; 29:908-915.
187. 3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion study. Aliment Pharmacol Ther 1997; 11:1109-1114.
188. 3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2000; 14:775-782.
189. Thumshirn M, Coulie B, Camilleri M, Zinsmeister AR, Burton DD, Van Dyke C. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14:869-878.
190. 3 receptor antagonist, has no effect on oro-caecal transit time in man. Dig Dis Sci 1996; 41:1996.
191. 3 receptor antagonist, does not perturb normal human small bowel motor patterns. Gastroenterology 1998; 114:A811.
192. Viramontes B, McKinzie S, Pardi DS, Burton D, Thomforde GM, Camilleri M. Alosetron retards small bowel and overall colonic transit in diarrhoea-predominant irritable bowel syndrome (D-IBS). Gastroenterology 2000; 118:A848.
193. Clemens C, Samsom M, Van Berge Henegouven G, Fabri M, Smout A. The effect of alosetron on periprandial phasic motility in non-constipated IBS patients and healthy volunteers. Gut 2000; 47 (suppl III):A209.
194. Clemens C, Samsom M, Van Berge Henegouven G, Fabri M, Smout A. The effect of alosetron on high-amplitude propagated pressure waves in non-constipated IBS patients and healthy volunteers. Gut 2000; 47 (suppl III):A40.
195. Solvay Pharm. Cilansetron: Investigational Drug Brochure, 6th edn. Hanover, Germany: Solvay Pharm; 1999.
196. Drew J, Belginger C, Meier R, Krause G, Steinborn C. Oral cilansetron produced increases in colonic transit time and gastric emptying in young and old healthy volunteers. Digestion 1998; 59 (suppl 3):665.
197. 3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man; a double blind cross over trial. Br J Clin Pharmacol 2000; 49:429-436.
198. 1p receptors on sensory CGRP neurons. Am J Physiol 1996; 270:G778-G782.
199. Foxx-Orenstein AE, Kuemmerle JF, Grider JR. Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine. Gastroenterology 1996; 111:1281-1290.
200. Pan H, Wade PR, Gershon MD. Activation of and transmission from intrinsic sensory neurons of the submucosal plexus. Gastroenterology 1997; 112:A803.
201. 4 receptor agonist initiates the peristaltic reflex in human, rat and guinea pig intestine. Gastroenterology 1998; 115:370-380.
202. Nguyen A, Camilleri M, Kost LJ, Metzger A, Sarr MG, Hanson RB, et al. SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J Pharmacol Exp Ther 1997; 280:1270-1276.
203. 4 agonist (SDZ HTF 919) and its main metabolite in conscious dogs: effects on gastrointestinal motility and impaired gastric emptying. Gastroenterology 1998; 114:A752, G3103.
204. 4 receptor agonist, accelerates gastrointestinal (G.I) tract. Gastroenterology 2000; 118:A863.
205. 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15:1745-1751.
206. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocaecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118:463-469.
207. 4 agonist HTF 919 improves symptoms of constipation predominant irritable bowel syndrome (C-IBS). Digestion 1998; 59 (suppl 3):735.
208. 4 partial agonist, tegaserod, improves abdominal discomfort/pain and normalises altered bowel function in irritable bowel syndrome (IBS). Am J Gastroenterol 1999; 94:2676.
209. Lefkowitz MP, Shi Y, Heggland J, Dunger-Baldauf C, Rüegg PC. Tegaserod rapidly improves abdominal pain, bloating and bowel function in patients with C-IBS. Gut 2000; 47 (suppl III):A217.
210. 4 agonist (HTF 919) improves symptoms in constipation-predominant irritable bowel syndrome (C-IBS). Digestion 1998; 59 (suppl 3):20.
211. 4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome in patients with abdominal pain, btoating and constipation. Aliment Pharmacol Ther 2001; 15:1655-1666.
212. 4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome (IBS). Gastroenterology 2000; 118 (suppl 2):A175.
213. 4 agonist, improves abdominal bloating and altered stool consistency in irritable bowel syndrome (IBS). Am J Gastroenterol 1999; 94:2685.
214. Whorwell P, Mueller-Lissner S, Langaker KJ, Wald A, Pruitt R, Rüegg PC;. Short and long-term safety and tolerability of tegaserod (HTF 919) in patients with irritable bowel syndrome (IBS). Gut 1999; 45 (suppl V):A160.
215. Whorwell PJ, Krumholz S, Mueller-Lissner S, Schmitt C, Dunger-Baldauf C, Rüegg PC. Tegaserod has a favourable safety and tolerabirity profile in patients with constipation predominant and alternating forms of irritable bowel syndrome. Gastroenterology 2000; 118 (suppl 2):A1204.
216. Rawls J, Lefkowitz M, Shi Y, Zack A, Dunger-Baldauf C, Rüegg PC. Tegaserod is well tolerated in diarrhoea-predominant irritable bowel syndrome. Gut 2000; 47 (suppl III):A217.
217. Briejer MR, Meulemans AL, Bosmans J-P, Akkermans LM, Schuurkes JA. In vitro pharmacology of the novel enterokinetic RO93877. Gastroenterology 1997; 112:A705.
218. 4 receptors mediate the RO93877-induced changes in contractile patterns in the canine colon. Gastroenterology 1997; 112:A705.
219. 4 receptor agonist, prucalopride, on cotonic motility in healthy volunteers. Aliment Pharmacol Ther 2002; 16:603-612.
220. Emmanuel AV, Kamm MA, Roy AJ, Antonelli K. Effect of a novel prokinetic drug, RO93877, on gastrointestinal transit in healthy volunteers. Gut 1998; 42:511-516.
221. 4 agonist, prucalopride, in healthy humans. Gut 1999; 44:682-686.
222. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001; 120:354-360.
223. Camilleri M, McKinzie S, Burton DD, Thomforde GM, Zinsmeister AR, Bouras EP. Prucalopride accelerates small bowel and colonic transit in patients with chronic functional constipation or constipation predominant irritable bowel syndrome. Gastroenterology 2000; 118:A863.
224. Johanson JF, Miner PB, Parkman HP, Wojcick MA, Lambert R, Karcher K, Woods M. Prucalopride improves bowel movement, frequency and symptoms in patients with chronic constipation: results of two double blind placebo controlled trials. Gastroenterology 2000; 118 (suppl 2):A195.
225. Gorbach SL. Probiotics and gastrointestinal health. Am J Gastroenterol 2000; 95 (suppl 1):S2-S4.
226. Shanahan F. Probiotics in inflammatory bowel disease. Gut 2001; 48:609.
227. Isolauri E, Juntunen M, Rautanen T, Ling WH, Salminen S. A human Lactobacillus strain GG (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhoea in children. Pediatrics 1991; 88:90-97.
228. Pochapin M. The effect of probiotics in Clostridium difficile diarrhoea. Am J Gastroenterol 2000; 95 (suppl 1):S11-S13.
229. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11:853-858.
230. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354:635-639.
231. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:305-309.
232. Nobaek S, Johanssen M-L, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction of abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95:1231-1238.
233. Niedzielin K, Kordecki H, Birkenfeld B. A controlled double-blind randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13:1143-1147.
234. O'Sullivan MA, O'Moraine CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double blind placebo controlled study. Dig Dis Sci 2000; 32:294-301.
235. Sen S, Mullan M, Parker TJ, Woolner J, Tarry SA, Hunter JO. Effects of Lactobacillus plantarum 299v on symptoms and colonic fermentation in irritable bowel syndrome (IBS). Gut 2001; 48 (suppl 1):A57.
236. Grant-Thompson W. Probiotics for irritable bowel syndrome: a light in the darkness? Eur J Gastroenterol Hepatol 2001; 13:1135-1136.
237. Rome II: a multinational consensus document on functional gastrointestinal disorders. Gut 1999; 45 (suppl II):II1-II81.
238. Lennard-Jones JE. Clinical classification of constipation. In: Kamm MA, Lennard-Jones JE (editors). Constipation. Petersfield, UK: Wrightson Biomedical Publishing; 1994. pp. 3-10.
239. Reid NW. Constipation in irritable bowel syndrome. In: Kamm MA, Lennard-Jones JE (editors). Constipation. Petersfield, UK: Wrightson Biomedical Publishing; 1994. pp. 157-160.
240. Bannister JJ, Timm SM, Barfield LJ, Donnelly TC, Reid NW. Physiological studies in young women with chronic constipation. Int J Colorectal Dis 1986; 1:175-182.
241. Prior A, Serial E, Sun WM, Read NW. Irritable bowel syndrome: differences between patients who show rectal sensitivity and those who do not. Eur J Gastroenterol Hepatol 1993; 5:343-349.
242. Bouin M, Plourde V, Bovin M, Riderdy M, Lupion F, Langaniere M, Verrier P, Poitras P. Rectal distension testing in patients with irritable bowel syndrome: sensitivity, specificity and predictive values of pain sensory thresholds. Gastroenterology 2002; 122:1771-1777.
243. Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101:927-934.
244. Clark ML, Silk DBA. Gastrointestinal disease. In: Kumar P, Clark M (editors). Clinical Medicine. London: WB Sanders; 2002. pp. 253-334.
245. Stanghellini V, Camilleri M, Malagelada J-R. Chronic idiopathic intestinal pseudo-obstruction: clinical and intestinal manometric findings. Gut 1987; 28:5-12.
246. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics and referral. Gut 2000; 46:78-82.